Credence

Sandoz Launches Enzeevu Prefilled Syringe in U.S., Signs Private-Label Biosimilar Agreement


Key Points

  • Sandoz launched Enzeevu (aflibercept-abzv) 2 mg in a prefilled syringe in the U.S. for retinal conditions including wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic retinopathy, and diabetic macular edema.
  • Enzeevu is FDA-approved, designated interchangeable with Eylea, and demonstrated clinical equivalence to the reference product in efficacy and safety.
  • Sandoz signed a multi-year private-label agreement for a second U.S. commercial channel for Enzeevu, expected to begin in mid-2027 with committed product volumes.

Sandoz has launched its aflibercept biosimilar Enzeevu in the United States, adding another ophthalmology product to its portfolio while establishing a multi-year private-label agreement designed to expand the drug’s commercial reach beginning in 2027.

The company announced November 16 that Enzeevu (aflibercept-abzv) 2 mg is now available in the U.S. in a prefilled syringe. The FDA-approved therapy is indicated for several retinal conditions, including neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), and diabetic macular edema (DME). Together, these conditions affect more than 30 million Americans.

The launch represents another step in Sandoz’s efforts to increase competition and expand access to biologic treatments in the ophthalmology market. Retinal diseases are a major cause of vision loss, particularly among people over age 50, and can significantly affect patients’ independence and ability to carry out everyday activities.

The FDA approved Enzeevu in August 2024. The product has the same dosage form, route of administration, and presentation as its reference biologic, Eylea (aflibercept). According to Sandoz, Enzeevu demonstrated clinical equivalence to the reference product in efficacy and safety and satisfied FDA biosimilarity requirements. The product is also designated interchangeable with Eylea across all approved indications.

Enzeevu contains aflibercept, a recombinant fusion protein that binds to vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF). By inhibiting these growth factors, the drug helps prevent abnormal blood vessel formation and reduce vascular permeability associated with retinal disease.

Administered through intravitreal injection, Enzeevu is indicated for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic retinopathy, and diabetic macular edema.

In addition to marketing Enzeevu under its own label, Sandoz has signed a multi-year private-label agreement that will create a second commercial channel in the U.S. Under the arrangement, Sandoz will manufacture the biosimilar for private-label commercialization, with the program expected to begin in mid-2027. The agreement includes committed product volumes starting in the second half of that year.

Sandoz said the deal builds on its experience bringing private-label biosimilars to the U.S. market, including its introduction of the first biosimilar offered through a private-label arrangement. The additional commercial channel is expected to support broader distribution and contribute to sales growth.

The Enzeevu launch also expands Sandoz’s presence in ophthalmology. The company acquired U.S. biosimilar Cimerli (ranibizumab-eqrn) in 2024 and introduced Afqlir (aflibercept) in Europe in 2025. The U.S. anti-VEGF market, which includes therapies used to treat retinal conditions, is estimated to be worth approximately $9.6 billion.

The launch further supports Sandoz’s Bio100 strategy, under which the company aims to have more than 100 biosimilars in its portfolio by 2040. The initiative is intended to expand the company’s coverage of biologics approaching loss of exclusivity, with Sandoz targeting approximately 80% coverage from 2035 onward.

Visit www.sandoz.com to learn more.